These results suggest HER2-low and HER2-zero breast cancers share largely similar features and outcomes; however, in certain subgroups, HER2-low tumors were associated with significantly better DFS, possibly reflecting differences in tumor biology. Further research is essential to clarify the biological role of HER2-low expression. This evidence concerns the gene ERBB2 and neoplasm.